Fig. 6

Fig. 6

Ruxolitinib can reverse the phenotype caused by the PDGFRβ.^Y562D in zebrafish. A The timeline of human WT/Y562D PDGFRβ mRNA treatment and medication administration: Embryos are injected human WT/Y562D PDGFRβ mRNA at one-cell stage and treated with Ruxolitinib at 24 h post-fertilization (24 hpf) and preserve at 3 days post-fertilization (3 dpf). B and C Immunostaining of kdrl:eGFP + cells and erythrocytes(αe1) in the head of a 3 dpf embryos treated or not with Ruxolitinib. Statistical significance is determined using Student's t-test and Benjamini–Hochberg correction. ns, no significant; *padj < 0.05, **padj < 0.01, ***padj < 0.001, ****padj < 0.0001